Yasaman Zohrab Beigi, Hossein Lanjanian, Reyhane Fayazi, Mahdieh Salimi, Behnaz Haji Molla Hoseyni, Mohammad Hafez Noroozizadeh, Ali Masoudi-Nejad
{"title":"黑色素瘤的异质性和分子结构:对靶向治疗的影响。","authors":"Yasaman Zohrab Beigi, Hossein Lanjanian, Reyhane Fayazi, Mahdieh Salimi, Behnaz Haji Molla Hoseyni, Mohammad Hafez Noroozizadeh, Ali Masoudi-Nejad","doi":"10.1186/s43556-024-00182-2","DOIUrl":null,"url":null,"abstract":"<p><p>Uveal cancer (UM) offers a complex molecular landscape characterized by substantial heterogeneity, both on the genetic and epigenetic levels. This heterogeneity plays a critical position in shaping the behavior and response to therapy for this uncommon ocular malignancy. Targeted treatments with gene-specific therapeutic molecules may prove useful in overcoming radiation resistance, however, the diverse molecular makeups of UM call for a patient-specific approach in therapy procedures. We need to understand the intricate molecular landscape of UM to develop targeted treatments customized to each patient's specific genetic mutations. One of the promising approaches is using liquid biopsies, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), for detecting and monitoring the disease at the early stages. These non-invasive methods can help us identify the most effective treatment strategies for each patient. Single-cellular is a brand-new analysis platform that gives treasured insights into diagnosis, prognosis, and remedy. The incorporation of this data with known clinical and genomics information will give a better understanding of the complicated molecular mechanisms that UM diseases exploit. In this review, we focused on the heterogeneity and molecular panorama of UM, and to achieve this goal, the authors conducted an exhaustive literature evaluation spanning 1998 to 2023, using keywords like \"uveal melanoma, \"heterogeneity\". \"Targeted therapies\",\" \"CTCs,\" and \"single-cellular analysis\".</p>","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":null,"pages":null},"PeriodicalIF":6.3000,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11082128/pdf/","citationCount":"0","resultStr":"{\"title\":\"Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.\",\"authors\":\"Yasaman Zohrab Beigi, Hossein Lanjanian, Reyhane Fayazi, Mahdieh Salimi, Behnaz Haji Molla Hoseyni, Mohammad Hafez Noroozizadeh, Ali Masoudi-Nejad\",\"doi\":\"10.1186/s43556-024-00182-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Uveal cancer (UM) offers a complex molecular landscape characterized by substantial heterogeneity, both on the genetic and epigenetic levels. This heterogeneity plays a critical position in shaping the behavior and response to therapy for this uncommon ocular malignancy. Targeted treatments with gene-specific therapeutic molecules may prove useful in overcoming radiation resistance, however, the diverse molecular makeups of UM call for a patient-specific approach in therapy procedures. We need to understand the intricate molecular landscape of UM to develop targeted treatments customized to each patient's specific genetic mutations. One of the promising approaches is using liquid biopsies, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), for detecting and monitoring the disease at the early stages. These non-invasive methods can help us identify the most effective treatment strategies for each patient. Single-cellular is a brand-new analysis platform that gives treasured insights into diagnosis, prognosis, and remedy. The incorporation of this data with known clinical and genomics information will give a better understanding of the complicated molecular mechanisms that UM diseases exploit. In this review, we focused on the heterogeneity and molecular panorama of UM, and to achieve this goal, the authors conducted an exhaustive literature evaluation spanning 1998 to 2023, using keywords like \\\"uveal melanoma, \\\"heterogeneity\\\". \\\"Targeted therapies\\\",\\\" \\\"CTCs,\\\" and \\\"single-cellular analysis\\\".</p>\",\"PeriodicalId\":74218,\"journal\":{\"name\":\"Molecular biomedicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2024-05-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11082128/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular biomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s43556-024-00182-2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43556-024-00182-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
葡萄膜癌(UM)的分子结构非常复杂,在遗传和表观遗传水平上都存在很大的异质性。这种异质性对这种不常见的眼部恶性肿瘤的行为和治疗反应起着至关重要的作用。使用基因特异性治疗分子进行靶向治疗可能有助于克服放射耐药性,但是,UM 的分子组成多种多样,因此在治疗过程中需要采用针对患者的方法。我们需要了解 UM 错综复杂的分子结构,以便针对每位患者的特定基因突变开发出针对性治疗方法。其中一种很有前景的方法是使用液体活检,如循环肿瘤细胞(CTC)和循环肿瘤 DNA(ctDNA),在早期阶段检测和监测疾病。这些非侵入性方法可以帮助我们为每位患者确定最有效的治疗策略。单细胞是一种全新的分析平台,能为诊断、预后和治疗提供宝贵的见解。将这些数据与已知的临床和基因组学信息相结合,可以更好地了解 UM 疾病所利用的复杂分子机制。在这篇综述中,我们重点关注 UM 的异质性和分子全景,为了实现这一目标,作者使用 "葡萄膜黑色素瘤"、"异质性"、"靶向治疗"、"免疫疗法"、"免疫治疗 "等关键词,对 1998 年至 2023 年的文献进行了详尽的评估。"靶向疗法"、"CTCs "和 "单细胞分析 "等关键词进行了详尽的文献评估。
Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.
Uveal cancer (UM) offers a complex molecular landscape characterized by substantial heterogeneity, both on the genetic and epigenetic levels. This heterogeneity plays a critical position in shaping the behavior and response to therapy for this uncommon ocular malignancy. Targeted treatments with gene-specific therapeutic molecules may prove useful in overcoming radiation resistance, however, the diverse molecular makeups of UM call for a patient-specific approach in therapy procedures. We need to understand the intricate molecular landscape of UM to develop targeted treatments customized to each patient's specific genetic mutations. One of the promising approaches is using liquid biopsies, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), for detecting and monitoring the disease at the early stages. These non-invasive methods can help us identify the most effective treatment strategies for each patient. Single-cellular is a brand-new analysis platform that gives treasured insights into diagnosis, prognosis, and remedy. The incorporation of this data with known clinical and genomics information will give a better understanding of the complicated molecular mechanisms that UM diseases exploit. In this review, we focused on the heterogeneity and molecular panorama of UM, and to achieve this goal, the authors conducted an exhaustive literature evaluation spanning 1998 to 2023, using keywords like "uveal melanoma, "heterogeneity". "Targeted therapies"," "CTCs," and "single-cellular analysis".